OBJECTIVES: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation. METHODS AND RESULTS: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without statin therapy. Although patients on statin therapy were older, their mean LTL was longer than patients not under statin therapy (1.29 ± 0.11 vs. 1.25 ± 0.11 T/S ratio, p = 0.008). In contrast, FOS and OGG1 mRNA levels were similar for the 2 groups. LTL decreased with increasing age, FOS, and OGG1 mRNA levels. Statin therapy remained associated with longer LTL, even after adjustment for confounding factors (p = 0.001), and in younger patients (≤ 64 y). Even in groups matched for propensity scores for statin use, LTL was markedly longer in patients under statin therapy. CONCLUSIONS: Our observational study showed that statin therapy was associated with longer LTL. These data bring to light opportunities to identify new targets for early primary preventive treatment strategies. Moreover, our study raised FOS and OGG1 as new relevant biomarkers of LTL.
OBJECTIVES: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation. METHODS AND RESULTS: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without statin therapy. Although patients on statin therapy were older, their mean LTL was longer than patients not under statin therapy (1.29 ± 0.11 vs. 1.25 ± 0.11 T/S ratio, p = 0.008). In contrast, FOS and OGG1 mRNA levels were similar for the 2 groups. LTL decreased with increasing age, FOS, and OGG1 mRNA levels. Statin therapy remained associated with longer LTL, even after adjustment for confounding factors (p = 0.001), and in younger patients (≤ 64 y). Even in groups matched for propensity scores for statin use, LTL was markedly longer in patients under statin therapy. CONCLUSIONS: Our observational study showed that statin therapy was associated with longer LTL. These data bring to light opportunities to identify new targets for early primary preventive treatment strategies. Moreover, our study raised FOS and OGG1 as new relevant biomarkers of LTL.
Authors: Belinda L Needham; Judith E Carroll; Ana V Diez Roux; Annette L Fitzpatrick; Kari Moore; Teresa E Seeman Journal: Health Place Date: 2014-05-22 Impact factor: 4.078
Authors: Daniel Lindqvist; Elissa S Epel; Synthia H Mellon; Brenda W Penninx; Dóra Révész; Josine E Verhoeven; Victor I Reus; Jue Lin; Laura Mahan; Christina M Hough; Rebecca Rosser; F Saverio Bersani; Elizabeth H Blackburn; Owen M Wolkowitz Journal: Neurosci Biobehav Rev Date: 2015-05-18 Impact factor: 8.989
Authors: Michael N Sack; Frej Y Fyhrquist; Outi J Saijonmaa; Valentin Fuster; Jason C Kovacic Journal: J Am Coll Cardiol Date: 2017-07-11 Impact factor: 24.094
Authors: Andrew J Pellatt; Roger K Wolff; Jennifer Herrick; Abbie Lundgreen; Martha L Slattery Journal: Mol Carcinog Date: 2012-02-21 Impact factor: 4.784
Authors: Kelly N H Nudelman; Jue Lin; Kathleen A Lane; Kwangsik Nho; Sungeun Kim; Kelley M Faber; Shannon L Risacher; Tatiana M Foroud; Sujuan Gao; Justin W Davis; Michael W Weiner; Andrew J Saykin Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472